Corcept Loses Patent Appeal in Teva Generic Korlym Dispute
Event summary
- The U.S. Court of Appeals for the Federal Circuit ruled that Teva Pharmaceuticals' generic version of Korlym does not infringe two of Corcept's patents related to safe co-administration with CYP3A4 inhibitors.
- The ruling upholds a December 2023 verdict by the Federal District Court for the District of New Jersey.
- Corcept's CEO, Joseph K. Belanoff, expressed disappointment and indicated the company will consider further judicial review.
The big picture
This ruling reinforces the challenges biotech companies face in defending patents against generic competitors, particularly in the crowded endocrinology space. Corcept's reliance on Korlym for revenue makes this dispute strategically significant, as it could impact the company's long-term market position and pricing power. The broader industry trend of increasing generic competition underscores the need for robust patent portfolios and alternative revenue streams.
What we're watching
- Patent Strategy
- How Corcept will respond to this setback in its patent defense strategy, particularly regarding Korlym's market exclusivity.
- Generic Competition
- The pace at which Teva and other generic manufacturers may expand their market share in Cushing’s syndrome treatments.
- Regulatory Dynamics
- Whether Corcept can successfully pursue further judicial review or negotiate alternative protections for its patented methods.
Our editorial coverage:
Related topics